youtube_live
Q2 2027 earnings • released • Revenue beat +1.47%
See resultschevron_right
4547:TYO
Kissei Pharmaceutical Co Ltd
Â¥4,400.00
arrow_upward
+12.53%(+490.00) 1D
Nov 17, 3:30:00 PM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
Â¥4,040
High
Â¥4,400
Low
Â¥4,010
Mkt. cap
204.78B
Avg. vol.
82.43K
Volume
544.20K
Dividend
2.84%
Quarterly dividend
Â¥31
Ex-dividend date
Mar 30, 2027
P/E ratio
16.31
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥270
Shares outstanding
46.72M
No. of employees
2K
Open
Â¥4,040
High
Â¥4,400
Low
Â¥4,010
Mkt. cap
204.78B
Avg. vol.
82.43K
Volume
544.20K
Dividend
2.84%
Quarterly dividend
Â¥31
Ex-dividend date
Mar 30, 2027
P/E ratio
16.31
52-wk high
Â¥5,040
52-wk low
Â¥3,500
EPS
Â¥270
Shares outstanding
46.72M
No. of employees
2K
News stories
From web sources and news partners
ChartMill
·
1 hour ago
S&P 500 After-Hours Gainers for Nov. 17, 2026
BigGo Finance
·
44 minutes ago
New York Stocks Slip a Day Before Nvidia Earnings; S&P 500, Nasdaq Fall for Fourth Straight Session
BigGo Finance
·
1 hour ago
Wall Street Split on 2027 S&P 500 Outlook: Wells Fargo's 8,200 vs. Morgan Stanley's 8,700
Traders Union
·
2 hours ago
Ryan Detrick: Technology stocks outperformed S&P 500 while 75 stocks declined
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79K
FoundedAug 9, 1946
HeadquartersMatsumoto, Nagano, Japan
SectorHealth Care
IndustryPharmaceutical industry
Websitekissei.co.jp